News
We send the latest information from SMC Laboratories.
Devonian Reports Positive Results in MASH Liver Study
In a great collaboration with Devonian Health Group Inc., we are happy to demonstrate preclinical proof of con…
CytoDyn Reports Significant Fibrosis Reversal in SMC Lab Studies
In a great collaboration with CytoDyn Inc., we are pleased to share promising preclinical results demonstratin…
【Breaking News!】 First MASH treatment approved by FDA
On March 14th, The United States Food and Drug Administration (FDA) announced their approval of Rezdiffra (res…
Cholangiocarcinoma and Primary sclerosing cholangitis
On February 15, World Cholangiocarcinoma Day! Today we would like to introduce cholangiocarcinoma (CCA,…
Press Release Regarding STAM-HCC/IO+ Mice has been distributed.
We are pleased to announce that our STAM(TM)-HCC/IO+ mouse was introduced in PR Newswire (Kyodo News JBN). For…
Announcement of webinar 【MASH-Liver cancer model mouse_Pharmacology study for MASH/fibrosis targeting GLP-1】
Today, we are excited to invite you to join our Webinar that will be taking place on January 25th from 9:30 AM…
Fibrosis is involved in many diseases and disease-related deaths
Today's topic is Fibrosis. We would like to discuss with you the importance of therapeutic treatments tha…
World COPD Day 2023 | “Breathing is Life – Act Earlier”
November 15th is World COPD Day, so why not learn more about COPD？ What is World COPD Day? World COPD D…
Exciting News! Galectin Therapeutics announces positive outcome of the fourth data from its seamless adaptive Phase 2b/3 trial of Belapectin (GR-MD-02) in liver cirrhosis due to NASH/MASH
Galectin Therapeutics (GA) announced on 3rd October, 2023, positive outcome of the fourth d ata and Safety Mon…
Exciting News from 89bio, Inc.! U.S. FDA has Granted Breakthrough Therapy Designation for Pegozafermin in NASH
The U.S. FDA has granted Breakthrough Therapy Designation (BTD) for 89bio, Inc.'s pegozafermin, a new dru…